Upstream Bio, Inc.
NASDAQ:UPBBiotechnology
Healthcare
$2.00 +1.63%
+$0.10 today
- Market cap
- $109.62M
- Beta
- 1.11
- P/E (TTM)
- -2.2
- EPS (TTM)
- -$2.89
52W Low $5.85High $33.68
Volume 0.86M
Average 0.66M
Income Statement
Follow revenue through to earnings.
Revenue
$2.85M
FY 2025 · Annual
+20.4% YoYOperating Income
-$160.36M
FY 2025 · Annual
Net Income
-$143.44M
FY 2025 · Annual
Income Statement
USD
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 1.21M | 2.38M | 2.37M | 2.85M |
| Cost of Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | 1.21M | 2.38M | 2.37M | 2.85M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% |
| Research & Development | 18.66M | 31.8M | 62.97M | 136.81M |
| Selling, General & Admin | 6.46M | 10.7M | 17.17M | 26.41M |
| Operating Expenses | 25.12M | 42.49M | 80.13M | 163.22M |
| Depreciation & Amortization | 7K | 60K | 89K | 188K |
| EBITDA | (23.86M) | (20.48M) | (62.72M) | (143.26M) |
| EBITDA Margin | -1968.7% | -860.4% | -2646.3% | -5019.4% |
| Operating Income | (23.91M) | (40.11M) | (77.76M) | (160.36M) |
| Operating Margin | -1972.7% | -1685.5% | -3281.2% | -5618.8% |
| Interest Income | 205K | 4.17M | 12.12M | 16.93M |
| Interest Expense | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 41K | 19.58M | 14.96M | 16.92M |
| Income Before Tax | (23.87M) | (20.54M) | (62.81M) | (143.44M) |
| Pre-Tax Margin | -1969.3% | -862.9% | -2650.0% | -5026.0% |
| Income Tax Expense | 0 | 0 | 0 | 0 |
| Net Income | (23.87M) | (20.54M) | (62.81M) | (143.44M) |
| Net Margin | -1969.3% | -862.9% | -2650.0% | -5026.0% |
| EPS (Basic) | (0.66) | (1.05) | (1.49) | (2.66) |
| EPS (Diluted) | (0.66) | (1.05) | (1.49) | (2.66) |
| 36.32M | 36.32M | 51.34M | 53.85M | |
| 36.32M | 36.32M | 51.34M | 53.85M |
UPB Earnings Waterfall · TTM
NASDAQ:UPB · Revenue to Net Income
Key Ratios
EPS$-2.91
Gross Margin98.8%
Net Margin-4872.1%
P/E Ratio-5.7
P/S Ratio1198.2
Analysis
$3.3M of revenue converted into -$156.8M of net income for the selected period. Gross margin is 98.8% and net margin is -4872.1%, showing how much revenue survives after costs and taxes. EPS is $-2.91, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 10, 2026 | |
| 8-K | Current report | Nov 10, 2026 | |
| SC 13G/A | SC 13G/A filing | Nov 6, 2026 | |
| SC 13G/A | SC 13G/A filing | Oct 29, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 17, 2026 |
How much revenue does UPB generate?
Upstream Bio, Inc. (UPB) reported $2.85M of revenue in fiscal 2025.
Is UPB profitable?
Upstream Bio, Inc. (UPB) reported -$143.44M of net income, with a net margin of -5026.0%.
Continue the stock analysis
Jump to another research area for this company.